Premium
The sustained release of LH · RH agonist from LH · RH agonist‐polymer composite in patients with prostatic cancer
Author(s) -
Imai Kyoichi,
Yamanaka Hidetoshi,
Yuasa Hisako,
Yoshida Masaro,
Asano Masaharu,
Kaetu Isao,
Yamazaki Iwao,
Suzuki Keiji
Publication year - 1986
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990080404
Subject(s) - agonist , medicine , luteinizing hormone , hormone , testosterone (patch) , endocrinology , cancer , prostate cancer , urology , chemistry , receptor
Luteinizing hormone‐releasing hormone (LH·RH) agonist can be administered daily to patients with prostatic cancer with resulting clinical efficacy. A sustained drug release formulation of an LH·RH agonist, (D‐Leu 6 )‐des Gly‐NH 2 10 ‐LH·RH ethylamide (leuprolide)‐vinyl polymer composite, was prepared by means of radiation‐induced polymerization under a supercooled state. The sustained release of leuprolide from subcutaneously implanted leuprolide‐vinyl polymer composite (14 mm in diameter and 4 mm in thickness) was obtained over a period of several months in five patients with prostatic cancer. Serum testosterone levels began to decrease on the tenth day, fell below 1 ng/ml after three weeks of implantation, and thereafter remained at the castration level until removal of the polymer composite. Clinical improvement was associated with serum hormonal changes, and support this as a novel and superior method of administration of LH·RH agonist.